Asthma and COPD Drug Market: Rising Prevalence of Chronic Diseases Driving the Market Growth

The market report titled ‘Global Asthma and COPD Drug Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.

Asthma and COPD Drug Market Drivers
The rising prevalence of chronic diseases is one of the factors fueling global asthma and COPD drug market.
According to the Centers for Disease Control and Prevention (CDC), in 2017, 19.9 million adults aged 18 and over have asthma. About 1 in 12 people have asthma, and the numbers are increasing every year.
According to Asthma UK, 5.4 million people in the UK have asthma, which is 1.1 million children and 4.3 million adults in 2016. In 2016 1,410 people died from asthma. In England, 4,500,000 people (1 in 11) have asthma. This consists of 932,000 children and 3,600,000 adults.
According to the World Health Organization (WHO), More than 65 million people around the world have moderate or severe COPD. The prevalence of COPD increased by 44.2 percent to 174.5 million individuals globally.

Request for a free sample of the report - https://www.datamintelligence.com/research-report/asthma-and-copd-drug-market/

Asthma and COPD Drug Market Size Analysis
Based on drug type, the global market for asthma and COPD drug is broadly segmented as by combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short-acting beta agonists (SABA), long-acting beta agonists (LABA), and others.
In September 2017, GlaxoSmithKline plc and Innoviva, Inc. have received the US Food and Drug Administration (FDA) has approval for single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trilogy Ellipta, with combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in addition treatment of airflow obstruction.

Asthma and COPD Drug Market Regional Analysis
Global asthma and COPD drug market are segmented into North America, Europe, Asia Pacific, South America, and ROW.
North America is dominating global asthma and COPD drug market, due to the regulatory approval and expansion of product portfolio by adding asthma and COPD drug, which is fueling the market growth.
In October 2018, Regeneron Pharmaceuticals, Inc. and Sanofi, have received the U.S. Food and Drug Administration approval for Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Asthma and COPD Drug Market Competitive Landscape
The strategic alliance between companies and regulatory approval for asthma and COPD drug is one of the critical factor driving global asthma and COPD drug market.
For instance, in December 2018, Teva Pharmaceutical Industries Ltd. have received the U.S. Food and Drug Administration (FDA) approval for ProAir Digital (albuterol sulfate 117 mcg) inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD.
In September 2017, Pulmatrix, Inc. partnered with Vectura Group plc to develop Pulmatrix’s drug, PUR0200, for chronic obstructive pulmonary disease (COPD) for the U.S. market.

Read more information about the research report - https://www.datamintelligence.com/research-report/asthma-and-copd-drug-market/
Table of contents overview -
1. Asthma and COPD Drug Market Scope and Methodology
2. Asthma and COPD Drug Industry Trends
3. Asthma and COPD Drug Market Outlook
4. Market Segmentation Analysis
4.1. BY DRUG TYPE
5. Regional, Country-level Analysis
5.1. Geographic Overview
5.2. North America
5.3. Europe
5.4. South America
5.5. Asia Pacific
5.6. Rest of World
6. Competitive Analysis
7. Company Profiles
8. Key companies to watch
9. Emerging Companies
10. Appendix

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

Market Research for long has been losing its credibility owing to low reliability and high proportions of estimations. Having identified this gap, DataM was established to provide businesses with reliable and near-market intelligence. This approach not only aligns the findings with historical data but also allows a highly justifiable forecast model.

This release was published on openPR.